Key facts
- This page summarizes Stuart A. Randle's Form 4 filing for Comera Life Sciences Holdings, Inc..
- 1 reported transaction and 1 derivative row are listed below.
- Accepted by SEC: 01 Sep 2023, 16:43.
Stuart A. Randle - 31 Aug 2023 Form 4 Insider Report for Comera Life Sciences Holdings, Inc.
- Reporting relationship
- Director
- Issuer ticker
- N/A
- Reported as of
- 31 Aug 2023
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 01 Sep 2023, 16:43:00 UTC
- Prior SEC filing
- 12 Jun 2023
- Next SEC filing
- 09 May 2024
- Source filing
- View source filing
- Reporting owner signature
- /s/ Ryan M. Rourke Reed, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Stuart A. Randle filed Form 4 for Comera Life Sciences Holdings, Inc. on 01 Sep 2023.
Change
- Previous filing in this sequence was filed on 12 Jun 2023.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
CMRA
transaction
Derivative
Stock Option (Right to Purchase)
Award
- Transaction value
- $0
- Shares
- +96,378
- Change %
- Price
- $0.000000
- Shares after
- 96,378
- Date
- 31 Aug 2023
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 96,378
- Exercise price
- $0.6995
- Footnotes
- F1, F2, F3
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 3 footnotes
Footnote F1
The option grant was approved by the registrant's board of directors on August 10, 2023, subject to stockholder approval of an amendment to the Comera Life Sciences Holdings, Inc. 2022 Equity and Incentive Plan (the "Plan") under which the option was granted. The registrant's stockholders approved the Plan amendment on August 31, 2023.
Footnote F2
The options became fully vested on the date the Plan amendment was approved by the registrant's stockholders.
Footnote F3
In furtherance of the registrant's cash conservation efforts, the options were granted in lieu of the annual cash retainer and committee fees due to non-employee directors for the quarter ended June 30, 2023, in accordance with the registrant's February 2023 temporary modification to its non-employee director compensation plan. This option was issued to the reporting person in lieu of retainer fees of $20,625. For more information related to the registrant's non-employee director compensation plan and the February 2023 temporary modification, see the registrant's Annual Report on Form 10-K for the year ended December 31, 2022.